A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Trial Details

NCT ID

NCT05827016

Phase

PHASE3

Sponsor

Bristol-Myers Squibb

Status

RECRUITING

Cancer Type

Newly Diagnosed Multiple Myeloma

Interventions

• Iberdomide
• Lenalidomide

Locations (sample)

• Aurora, Colorado, United States|39.72943,-104.83192
• Jacksonville, Florida, United States|30.33218,-81.65565
• Tampa, Florida, United States|27.94752,-82.45843
• Athens, Georgia, United States|33.96095,-83.37794
• Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

• Confirmed diagnosis of symptomatic multiple myeloma (MM).
• Eastern Cooperative Oncology Group performance status (ECOG) score of 0, 1, or 2.
• Received 3 to 6 cycles of an induction therapy that includes a proteasome inhibitor (PI) and immunomodulatory (IMiD) \[eg, bortezomib thalidomide a…
• Participants within 12 months (single transplant) or 15 months (tandem transplant) from initiation of induction therapy who achieved at least a par…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.